背景:益生元半乳寡糖(GOS)增加了妇女和儿童中作为富马酸亚铁(FeFum)给予的强化水平铁剂量的铁吸收。无论是GOS还是其他纤维,例如益生元低聚果糖(FOS)和阿拉伯胶,从较高剂量的FeFum中增加铁吸收尚不清楚。
目的:在缺铁[血清铁蛋白(SF)<25μg/L]的女性中,我们测试了15克GOS的口服联合给药,FOS,或阿拉伯胶增加了作为FeFum的100mgFe补充剂的铁吸收。
方法:在随机分组中,单盲,交叉研究,30名女性(中位年龄:26.2岁;中位SF:12.9μg/L)服用了标有4mg57Fe或58Fe的100mgFe片剂,给予1)15克GOS;2)15克FOS;3)15克阿拉伯胶;或4)6.1克乳糖和1.5克蔗糖(对照;匹配GOS粉末中存在的蔗糖和乳糖的量,提供15克GOS),溶解在水中。主要结果,分数铁吸收(FIA),给药后14d通过红细胞同位素掺入进行评估。使用线性混合效应模型分析数据。我们还测试了,在体外,来自体内施用的不同补充剂组合的不同pH下的铁溶解度和透析性。
结果:FIA来自FeFum的GOS和FOS明显更高(+45%和+51%,分别;两者均P<0.001)比对照组;[IQR]总铁吸收中位数为34.6mg[28.4-49.1mg],36.1毫克[29.0-46.2毫克],和23.9毫克[20.5-34.0毫克],分别。金合欢胶对FeFum的FIA没有显着影响(P=0.688)。体外,FeFumGOS的铁透析能力比单独的FeFum高46%(P=0.003)。
结论:在缺铁的女性中,GOS和FOS与FeFum共同给药可使100mg口服铁剂量的铁吸收增加50%,导致额外的10-12毫克的铁吸收。因此,GOS和FOS可能是有希望的补充铁吸收的新增强剂。该试验在clinicaltrials.gov注册为NCT04194255。
Prebiotic galacto-oligosaccharides (GOS) increase iron absorption from fortification-level iron doses given as ferrous fumarate (FeFum) in women and children. Whether GOS or other fibers, such as prebiotic fructo-oligosaccharides (FOS) and acacia gum, increase iron absorption from higher supplemental doses of FeFum is unclear.
In iron-depleted [serum ferritin (SF) <25 μg/L] women, we tested if oral coadministration of 15 g GOS, FOS, or acacia gum increased iron absorption from a 100 mg Fe supplement given as FeFum.
In a randomized, single-blind, crossover study, 30 women (median age: 26.2 y; median SF: 12.9 μg/L) consumed a 100 mg Fe tablet labeled with 4 mg 57Fe or 58Fe, given with either 1) 15 g GOS; 2) 15 g FOS; 3) 15 g acacia gum; or 4) 6.1 g lactose and 1.5 g sucrose (control; matching the amounts of sucrose and lactose present in the GOS powder providing 15 g GOS), dissolved in water. The primary outcome, fractional iron absorption (FIA), was assessed by erythrocyte isotopic incorporation 14 d after administration. Data were analyzed using a linear mixed-effect model. We also tested, in vitro, iron solubility at different pH and dialyzability from the different supplement combinations administered in vivo.
FIA from FeFum given with GOS and FOS was significantly higher (+45% and +51%, respectively; P < 0.001 for both) than control; median [IQR] total iron absorption was 34.6 mg [28.4-49.1 mg], 36.1 mg [29.0-46.2 mg], and 23.9 mg [20.5-34.0 mg], respectively. Acacia gum did not significantly affect FIA from FeFum (P = 0.688). In vitro, iron dialyzability of FeFum + GOS was 46% higher than that of FeFum alone (P = 0.003).
In iron-depleted women, both GOS and FOS coadministration with FeFum increased iron absorption by ∼50% from a 100 mg oral iron dose, resulting in an additional 10-12 mg of absorbed iron. Thus, GOS and FOS may be promising new enhancers of supplemental iron absorption. This trial was registered at clinicaltrials.gov as NCT04194255.